Bictegravir vs Dolutegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Bictegravir · Biktarvy

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT02607956 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.

Next expected readout: December 2026 · NCT06830668 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)

Result source: NCT03110380

Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)

Marketed by GlaxoSmithKline and partners

Approved in HIVsmall molecule
Reliable signal

NCT01263015 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)

Result source: NCT01263015

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravirDolutegravir
HIV-1 RNA below 50 copies/mL (week 48)92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764
HIV-1 RNA 50 copies/mL or more (week 48)0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380—Not posted · NCT01837277
CD4 count, change (week 48)278 vs 289vs DTG + F/TAFwk 144 · n 262NCT02607956
6 other results
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir
92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
Dolutegravir
88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
Dolutegravir
—Not posted · NCT01837277

CD4 count, change (week 48)

Bictegravir
278 vs 289vs DTG + F/TAFwk 144 · n 262NCT02607956
6 other results
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
Dolutegravir
163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Bictegravir: 7 of 7 rows · Dolutegravir: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBictegravir
Rows use multiple source trials
Dolutegravir
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
382.4211 cells/uL @ 48wka,b,c
NCT04530630 · Phase 4 · registry result, not featured evidence
110 cells/uL @ 48wk50 mg BIDa,b,c
NCT01328041 · Phase 3
HIV-1 RNA
absolute change · log
Induction
-3.03 vs -3.15 DTG + F/TAF log @ 12wkd,b
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.01 vs -2.85 EFV/TDF/FTC log @ 12wk50 mg plus 600/300 mg once dailyd,b
NCT01263015 · Phase 3 · combination · HIV · phase 3
4 other source trials
-2.908 vs -2.918 RTG log @ 12wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.88 vs -2.61 DRV + RTV log @ 12wk50 mg once daily
NCT01449929 · Phase 3
-2.756 vs -2.541 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 12wk
NCT01910402 · Phase 3 · registry result, not featured evidence
-1.54 vs -2.02 placebo log @ 12wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
Maintenance
-3.06 vs -3.11 DTG + F/TAF log @ 144wke,c
NCT02607956 · Phase 3 · HIV · phase 3
1 other source trial
-3.11 vs -3.1 ABC/DTG/3TC log @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.02 vs -3.04 EFV/TDF/FTC log @ 144wk50 mg plus 600/300 mg once dailye,c
NCT01263015 · Phase 3 · combination · HIV · phase 3
Dropout rate
18.7%f
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
17.1%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
11.9%
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
20%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
17.4%50 mg plus 600/300 mg once dailyg
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
26%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
13.6%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
31.1%50 mg BID
NCT01328041 · Phase 3
8.5%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
10.7%
NCT04585737 · Phase 4 · registry result, not featured evidence
25.6%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
13.1%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
16.2%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
11.4%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
7.8%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
4.7%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
0%50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
0%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
0%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
23.9%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
0%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
1.5%
NCT03991013 · Phase 2 · registry result, not featured evidence
3.8%
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1.2%f
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
0%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
—
NCT04530630 · Phase 4 · registry result, not featured evidence
—
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
3.1%50 mg plus 600/300 mg once dailyg
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
2.9%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
2.1%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
3.8%50 mg BID
NCT01328041 · Phase 3
—
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
—
NCT04585737 · Phase 4 · registry result, not featured evidence
—Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
—Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
7.7%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—
NCT01837277 · Phase 2/3 · registry result, not featured evidence
—50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
—50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
—
NCT03991013 · Phase 2 · registry result, not featured evidence
—
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Serious AEs
20%f
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
14%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
4%
NCT05405751 · Phase 4 · registry result, not featured evidence
0%
NCT03656783 · Phase 3 · registry result, not featured evidence
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
15.7%50 mg plus 600/300 mg once dailyg
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
10%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
6.2%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg once daily
NCT01449929 · Phase 3
14.9%50 mg once daily
NCT01449929 · Phase 3
3.3%50 mg once daily
NCT01449929 · Phase 3
25.1%50 mg BID
NCT01328041 · Phase 3
9.9%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
8.1%
NCT04585737 · Phase 4 · registry result, not featured evidence
7.7%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
8.2%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
2.1%DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
10.4%DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
3.6%DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
10.8%DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
18%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
18.1%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
35.7%50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
26.2%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
10%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
14.9%Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
6.1%Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
9.8%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
6.9%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
3.1%
NCT03991013 · Phase 2 · registry result, not featured evidence
0%
NCT03851588 · Phase 2 · registry result, not featured evidence
0%Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
7.1%Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
f
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · HIV · phase 3
show 12 more results
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · combination
loose stool/ diarrhea 25%
NCT04530630 · Phase 4 · registry result, not featured evidence
shortness of breath 8%
NCT03656783 · Phase 3 · registry result, not featured evidence
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
50 mg
fatigue 25% (placebo 0%)
papule 25% (placebo 0%)
arthropod bite 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
100 mg
arthropod bite 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
25 mg
headache 25% (placebo 25%)
arthropod bite 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
5 mg
blood creatine phosphokinase increased 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
50 mg plus 600/300 mg once dailyg
diarrhoea 22.7%
nasopharyngitis 20.8%
insomnia 17.9%
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 31 more results
50 mg Once a Day
nausea 14.6%
diarrhoea 14.1%
headache 13.6%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg Once a Day
upper respiratory tract infection 8%
syphilis 7.1%
viral upper respiratory tract infection 7.1%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg once daily
diarrhoea 17.8%
headache 16.5%
nausea 16.5%
NCT01449929 · Phase 3
50 mg once daily
viral upper respiratory tract infection 4.1%
gastroenteritis 2.4%
asthenia 1.6%
NCT01449929 · Phase 3
50 mg BID
diarrhoea 22.4%
cough 15.8%
nausea 14.2%
NCT01328041 · Phase 3
insomnia/nightmares 3.9%
alopecia 2%
itching/rash/prurigo 2%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
nausea 4.7%
fatigue 4%
diarrhea 3.4%
NCT04585737 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.7%
headache 8.1%
urinary tract infection 6%
NCT01910402 · Phase 3 · registry result, not featured evidence
nausea 18.5%
headache 11.7%
diarrhoea 9.3%
NCT01910402 · Phase 3 · registry result, not featured evidence
covid-19 6.9%
suspected covid-19 3.4%
headache 3%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
headache 14.3%
diarrhoea 14%
nasopharyngitis 13.8%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
covid-19 6%
syphilis 4%
respiratory tract infection viral 3.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.6%
upper respiratory tract infection 13.1%
nasopharyngitis 12.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 83.9%
blood creatinine increased 78.3%
haemoglobin decreased 3.7%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 89.8%
blood creatinine increased 83.3%
haemoglobin decreased 9.3%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
grade 3 bilirubinemia 0%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
50 mg OD
headache 53.8%
upper respiratory tract infection 38.5%
diarrhoea 30.8%
NCT01499199 · Phase 3 · registry result, not featured evidence
50mg BID
diarrhoea 21.4% (placebo 12.5%)
headache 21.4% (placebo 6.3%)
lymphadenopathy 21.4% (placebo 0%)
NCT01568892 · Phase 3 · registry result, not featured evidence
cns disturbances 0%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
50 mg od
low haemoglobin 6.9%
NCT02245022 · Phase 2/3 · registry result, not featured evidence
50 mg BID
abnormal loss of weight 10%
blood pressure increased 10%
headache 10%
NCT05630872 · Phase 2 · registry result, not featured evidence
acute psychosis 1.5% (placebo 0%)
incident pulmonary tuberculosis 1.5% (placebo 0%)
acute kidney injury 0% (placebo 3.1%)
NCT03991013 · Phase 2 · registry result, not featured evidence
insomnia 5.7% (placebo 0%)
NCT03851588 · Phase 2 · registry result, not featured evidence
haemoglobin decreased 33.3%
alanine aminotransferase increased 16.7%
aspartate aminotransferase increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 50%
alanine aminotransferase increased 16.7%
blood bilirubin increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 83.3%
neutrophil count decreased 50%
acne infantile 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 42.9%
blood bilirubin increased 35.7%
dermatitis diaper 21.4%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 56.3%
neutrophil count decreased 31.3%
blood bilirubin increased 25%
NCT05406583 · Phase 1 · registry result, not featured evidence
hypokalaemia 71.4% (placebo 71.4%)
hypoglycaemia 42.9% (placebo 71.4%)
vivid dreams 28.6% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
hypokalaemia 62.5% (placebo 71.4%)
cold 25% (placebo 14.3%)
bloating 12.5% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. ePopulation context differs: baseline_threshold differs (hiv_viral_load>=500 versus hiv_viral_load>=1000).
  6. fPopulation comparability has not been reviewed for 13 of these studies.
  7. gPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bictegravir

HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
Hip BMD -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-1.128% (n=250) vs -1.262% (n=257) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-1.02% (n=236) vs -1.291% (n=240) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
HIV-1 RNA Ge50 Copies 0.4% (n=284) vs 1.1% (n=281) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT03110380 · Phase 3
Virologic Suppression 100% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 19 Participants as posted
CD4 25.667% (n=19) @ 4wk
percent change · % of baseline
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence
show 4 more results
25.7368% (n=19) @ 12wk
NCT04530630 · Phase 4 · registry result, not featured evidence
27.0526% (n=19) @ 24wk
NCT04530630 · Phase 4 · registry result, not featured evidence
28.1111% (n=19) @ 36wk
NCT04530630 · Phase 4 · registry result, not featured evidence
26.1579% (n=19) @ 48wk
NCT04530630 · Phase 4 · registry result, not featured evidence
Allograft Rejection 0% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
CD4 170 vs 173 DTG + F/TAF count @ 12wk
absolute change · count
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
190 vs 155 DTG + F/TAF count @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
258 vs 188 DTG + F/TAF count @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination

Dolutegravir

Time to Viral Suppression 0.92 vs 2.79 DRV + RTV months50 mg once daily
time to event · months
NCT01449929 · Phase 3 · converted to months from 28 days as posted
show 3 more results
0.92 vs 2.76 EFV/TDF/FTC months*50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to months from 28 days as posted
0.95 vs 0.95 DTG + TDF/FTC months @ 144wk*
NCT02831673 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
0.95 vs 0.95 DTG + TDF/FTC months*
NCT02831764 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
Virologic Failure 2.7% (n=414) vs 1.9% (n=419) EFV/TDF/FTC50 mg plus 600/300 mg once daily
event count · % of participants
ACTG virologic failures
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to % from 11 Participants as posted
Symptom Bother -3.2 vs -2.19 DRV + RTV score @ 4wk50 mg once daily
absolute change · score
NCT01449929 · Phase 3
show 3 more results
-2.71 vs -1.65 DRV + RTV score @ 24wk50 mg once daily
NCT01449929 · Phase 3
-2.46 vs -0.77 DRV + RTV score @ 48wk50 mg once daily
NCT01449929 · Phase 3
-1.818 vs -1.246 EFV/TDF/FTC score50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Less Than 50 80.8% (n=411) vs 76.4% (n=411) RTG @ 96wk50 mg Once a Day
event count · % of participants
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 332 Participants as posted
HIV-1 RNA Less Than 400 89.8% (n=411) vs 86.6% (n=411) RTG @ 48wk50 mg Once a Day
event count · % of participants
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 369 Participants as posted
show 1 more result
82.2% (n=411) vs 78.1% (n=411) RTG @ 96wk*50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 338 Participants as posted
HIV-1 RNA Less Than 400 Copies 92% (n=242) vs 87% (n=242) DRV + RTV @ 48wk50 mg once daily
responder rate · % of participants
NCT01449929 · Phase 3
CD4+ 80.1 vs 75.6 DRV + RTV cells/uL @ 4wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 4, n=237, 236
NCT01449929 · Phase 3
CD4+ 126.9 vs 118.8 DRV + RTV cells/uL @ 8wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 8, n=236, 236
NCT01449929 · Phase 3
CD4+ 135.2 vs 131.8 DRV + RTV cells/uL @ 12wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 12, n=234, 228
NCT01449929 · Phase 3
CD4+ 156.8 vs 146.1 DRV + RTV cells/uL @ 16wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 16, n=227, 227
NCT01449929 · Phase 3
CD4+ 165.1 vs 164.3 DRV + RTV cells/uL @ 24wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 24, n=233, 227
NCT01449929 · Phase 3
CD4+ 206.1 vs 186.5 DRV + RTV cells/uL @ 36wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 36, n=232, 218
NCT01449929 · Phase 3

+ 77 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Dolutegravir's landscape